Pediatric Cancer Clinical Trials

5 trials identified.

ANBL1232 Study to Guide Therapy Non-High-Risk Neuroblastoma
Principal Investigator: Wagner, Lars
Protocol Number: PRO00059254

Age Group: Children
Scope: National

Phase: III (Cancer Control)
Disease Site: Brain and Nervous System

Contact: Wagner, Lars
Phone:

What is the Condition Being Studied?
Non-High Risk Neuroblastoma
What is the Purpose of this Study?
We are doing this study to figure out which children need treatment and what the best treatment is for newly diagnosed neuroblastoma.
Who Can Participate in the Study?
Children with newly diagnosed neuroblastoma who

Group A: Are less than 12 months old with newly diagnosed Stage L1 neuroblastoma.

Group B: Children who are less than 18 months old with newly diagnosed Stage L2 neuroblastoma.

Group C: Children who are less than 18 months old with newly diagnosed Stage Ms neuroblastoma.

No prior radiotherapy or chemotherapy, except dexamethasone, is allowed.
Children must not have had surgery to remove the primary tumor.
What is Involved?
If you choose to have your child this study, he or she will be put into a group based on certain features of their disease.

Group A is for children younger than one year old with newly diagnosed Stage L1 neuroblastoma
Subjects will be closely observed and will not have a biopsy or surgery on this trial.

Group B is for children younger than 18 months old with newly diagnosed Stage L2 neuroblastoma
Instead of starting treatment at diagnosis, these children will be closely monitored for tumor growth or spread. They may go on to have chemotherapy and/or have surgery if the tumor grows.

Group C is for children younger than 18 months with newly diagnosed Stage Ms neuroblastoma
Children who are very young and those with symptoms or unfavorable tumor features will start chemotherapy sooner than usual.

We will use a symptom scoring system to decide when to stop chemotherapy for all children who go on to have chemotherapy.


Participating Institutions:
  • Duke University Health System : Lars Wagner
View this trial at ClinicalTrials.gov

AGCT1531 for Standard Risk Pediatric and Adult Patients with Germ Cell Tumors
Principal Investigator: Wagner, Lars
Protocol Number: PRO00084265

Age Group: Both
Scope: National

Phase: III (Cancer Control)
Disease Site: Ovary

Contact: Wagner, Lars
Phone:

What is the Condition Being Studied?
Pediatric and Adult Patients with Germ Cell Tumors
What is the Purpose of this Study?
We are doing this study to see if we keep an eye on patients with low risk germ cell tumors after your tumor is removed, will it work like following surgery with chemotherapy and/or more surgery.

For the standard risk groups 1 and 2, we want to compare the effects of carboplatin with cisplatin for patients with standard risk germ cell tumors to find out which one is better. 


Who Can Participate in the Study?
Female children and adults who:
-Are aged 49 or younger
-Have primary extracranial germ cell tumor
-Have received prior systemic therapy 
What is Involved?
If you choose to join this study, you will:

-Be assigned to one of the following groups: 
-- Low risk, standard risk 1 or standard risk 2

If you are in:
- Low risk group:
-- Be closely watched for 2 years and less frequently for years 3-5
-- Get blood tests and imaging tests to see if your tumor has came back

- Standard risk 1 and 2 groups: 
-- Be put into one of two groups (Like the flip of a coin) to get chemotherapy with bleomycin, etoposide and either cisplatin (standard) or carboplatin (experimental). 
-- Get one of the two treatments for either 3 or 4 cycles that last 3 weeks (21 days) each.
-- Have tissue and scans from your tumor tested
Participating Institutions:
  • Duke University Health System : Lars Wagner
View this trial at ClinicalTrials.gov

APEC1621 Pediatric MATCH Study
Principal Investigator: Kreissman, Susan
Protocol Number: PRO00087722

Age Group: Both
Scope: National

Phase: II (Cancer Control)
Disease Site: Bones and Joints; Soft Tissue

Contact: Wagner, Lars
Phone:

What is the Condition Being Studied?
Solid tumors, non-Hodgkin lymphomas, sarcoma, CNS tumors
What is the Purpose of this Study?
We are doing this study to see if different study drugs or drug combinations that target specific genetic changes found in some cancers will shrink the tumor and/or prolong the time to progression. 
Who Can Participate in the Study?
Children and adults with recurrent solid tumors, lymphoma, and CNS tumors who:
- Are aged 12 months to less than 21 years of age 
- Have no uncontrolled infection
- Have had a prior solid organ transplant
What is Involved?
If you choose to join this study, you will:
- Have tumor tissue from a biopsy sent to a lab for genetic testing
-- If the tumor tissue has a genetic change that is targeted by one or more of the study drugs being tested in this study, you may be assigned to that study. 
Participating Institutions:
  • Duke University Health System : Lars Wagner
View this trial at ClinicalTrials.gov

ANBL1531: Newly Diagnosed High-Risk Neuroblastoma
Principal Investigator: Kreissman, Susan
Protocol Number: PRO00100226

Age Group: Both
Scope:

Phase: III
Disease Site: Brain and Nervous System

Contact: Sun, Jessica
Phone:

What is the Condition Being Studied?
Newly Diagnosed High-Risk Neuroblastoma
What is the Purpose of this Study?
We are doing this study to find out if we can improve the treatment for patients with high-risk neuroblastoma by adding the study drug 131I-MIBG (131I-metaiodobenzylguanidine) or the study drug crizotinib to the standard treatment.  
Who Can Participate in the Study?
Children and Adults with Neuroblastoma who:
- Are 1 year old and less than 30 years old
- Are able to tolerate peripheral blood stem cell collection
What is Involved?
If you choose to be in this study, you will:
- Be randomized (like drawing numbers out of a hat) to get either:
-- Group 1: Standard of care treatment
-- Group 2: Study drug 131I-MIBG and standard of care treatment
-- Group 3: Study drug 131I-MIBG and one stem cell transplant and standard of care chemotherapy
-- Group 4: Standard of care treatment 
-- Group 5: Study drug Crizotinib plus standard of care treatment 
- Have a scan and have tissue taken from your tumor sent for a test to see if it contains a specific gene
- Have standard treatment called induction therapy
Participating Institutions:
  • Duke Cancer Center Cary : Jessica Sun
  • Duke Center for Living/Sarah Stedman Nutrition : Jessica Sun
  • Duke Primary Care : Jessica Sun
  • Duke Private Diagnostic Clinic (PDC) : Jessica Sun
  • Duke Raleigh Hospital : Jessica Sun
  • Duke Regional Hospital : Jessica Sun
  • Duke University Health System : Jessica Sun
  • Duke Women's Cancer Care Raleigh (Macon Pond) : Jessica Sun
  • Johnston Health (Smithfield) : Jessica Sun
  • Maria Parham Health (Henderson) : Jessica Sun
  • Scotland Health Care System (Laurinburg) : Jessica Sun
  • Southeastern Regional Medical Center (Lumberton) : Jessica Sun
View this trial at ClinicalTrials.gov

AHEP1531: Hepatoblastoma in Children & Young Adults
Principal Investigator: Wagner, Lars
Protocol Number: PRO00101163

Age Group: Both
Scope:

Phase: II/III
Disease Site: Liver

Contact: Wagner, Lars
Phone:

What is the Condition Being Studied?
Children and young adults with Hepatoblastoma 
What is the Purpose of this Study?
We are doing this study to compare the effects (good and/or bad) of cisplatin with the combination of chemotherapy in treating children and young adults with hepatoblastoma or liver cancer after surgery.
Who Can Participate in the Study?
Adults and children who:
- Are up to age 30
- Have a newly diagnosed primary pediatric hepatic malignancy
What is Involved?
If you choose to join this study, you will:
- Get treatments based on the group you are assigned 

-- Group A: patients with very low risk disease
-- Group B: patients with low risk disease
-- Group C: patients with intermediate risk disease
-- Group D: patients with high risk disease

Depending on your assigned group, you may:
-- Get chemotherapy drugs such as cisplatin, doxorubicin, fluorouracil, vincristine sulfate, carboplatin, etoposide, irinotecan, sorafenib, gemcitabine and/or oxaliplatin.
--- Be randomized (like flipping a coin) to different types or doses of chemotherapy
-- Have surgery to remove your tumor
Participating Institutions:
  • Duke Cancer Center Cary : Lars Wagner
  • Duke Center for Living/Sarah Stedman Nutrition : Lars Wagner
  • Duke Primary Care : Lars Wagner
  • Duke Private Diagnostic Clinic (PDC) : Lars Wagner
  • Duke Raleigh Hospital : Lars Wagner
  • Duke Regional Hospital : Lars Wagner
  • Duke University Health System : Lars Wagner
  • Duke Women's Cancer Care Raleigh (Macon Pond) : Lars Wagner
  • Johnston Health (Smithfield) : Lars Wagner
  • Maria Parham Health (Henderson) : Lars Wagner
  • Scotland Health Care System (Laurinburg) : Lars Wagner
  • Southeastern Regional Medical Center (Lumberton) : Lars Wagner
View this trial at ClinicalTrials.gov